|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Product | |||||
| License | |||||
| Total revenues | |||||
| Costs and expenses: | |||||
| Cost of sales | |||||
| Royalties | |||||
| Research and development | |||||
| Depreciation and amortization | |||||
| Loss/(gain) on operating lease right-of-use assets | |||||
| Gain on operating lease right-of-use assets | |||||
| Total expenses | |||||
| Selling, general and administrative | |||||
| Total costs and expenses | |||||
| Loss from operations | |||||
| Interest income | |||||
| Interest expense | |||||
| Gain from sale of priority review voucher, net | |||||
| Other income, net | |||||
| Income (loss) before income taxes | |||||
| Income tax (benefit) expense | |||||
| Net income (loss) | |||||
| Net loss attributable to Common Shareholders | |||||
| Basic income (loss) per common share | |||||
| Dilutive income (loss) per common share | |||||
| Weighted average number of common shares outstanding: | |||||
| Basic | |||||
| Dilutive | |||||
| Other comprehensive income (loss): | |||||
| Change in unrealized gains related to available-for-sale debt securities | |||||
| Foreign currency translation adjustments | |||||
| Comprehensive income (loss) | |||||
Loading...